Innovative medical devices get a temporary 'tracking' CPT code. To secure permanent reimbursement, companies must demonstrate widespread physician adoption, but achieving that adoption is nearly impossible without the insurance coverage they are trying to obtain.
Related Insights
The new Medicare 'Access' code for AI in chronic care is priced too low to be profitable if humans are kept in the loop. This clever incentive design forces providers to adopt genuine AI-driven leverage rather than simply relabeling human effort, a first for healthcare technology.
For early-stage MedTech startups, key milestones for investors are not just regulatory successes. They are fundamental proofs of concept—showing the device works in a model and demonstrating how it would function in a clinical setting. This builds an investor's vision of the product's future.
The overactive bladder market is chronically underserved not due to a lack of options, but because existing treatments (drugs linked to dementia, expensive implants) are so flawed that 78% of patients refuse them. This massive patient drop-off signals a prime opportunity for safer, more accessible alternatives.
Beyond efficacy, new therapies like bispecifics require significant institutional support. Clinicians need training for unfamiliar side effects like CRS, and facilities need resources like observation units and admission protocols, creating a steep implementation curve for clinical practice.
General Catalyst's CEO highlights a core flaw in healthcare: insurance providers don't reimburse for longevity or preventative care because customers frequently switch plans, preventing insurers from capturing long-term ROI. The first company to solve this misalignment and make longevity "financeable" will unlock a massive market.
The ATX-101 implant was designed with surgeons to be simple and fast to use, fitting into natural pockets in the knee without special training. By saving 5-10 minutes per procedure compared to alternatives, it addresses a critical workflow pain point for physicians and hospitals, enhancing its commercial appeal.
While positioned as a clinical decision support tool rather than a formal diagnostic, the technology is still reimbursable under existing CPT codes. This provides a direct financial incentive for providers, a critical advantage in a healthcare system where new, unreimbursed technologies face steep adoption hurdles.
While wearables generate vast amounts of health data, the medical system lacks the evidence to interpret these signals accurately for healthy individuals. This creates a risk of false positives ('incidentalomas'), causing unnecessary anxiety and hindering adoption of proactive health tech.
Even after proving a device works, getting FDA clearance, and securing a reimbursement code, investors' final question is about market traction. They want to see revenue before funding the sales team required to generate it, creating a final catch-22.
The core issue preventing a patient-centric system is not a lack of technological capability but a fundamental misalignment of incentives and a deep-seated lack of trust between payers and providers. Until the data exists to change incentives, technological solutions will have limited impact.
